Mesenbio
1 known investors
Mesenbio develops extracellular vesicle (EV) therapeutics derived from mesenchymal stem cells, using its FT-01 platform to enable scalable, GMP-ready EV manufacturing for regenerative medicine. The company is advancing a licensing-ready production platform and preclinical therapeutic candidate (MEV-N01) targeting rheumatoid arthritis.
BiotechHealthtechLongevity
Founders & leadership
DD
Dr. David KuntinChief Executive Officer
PP
Prof. Paul GeneverChief Scientific Officer
AA
Anita AdamsFinance Director
Board
DD
Dr. David SimpsonChair
JG
Jason GoldsteinBoard director
Investors · 1
Frequently asked questions
- What does Mesenbio do?
- Mesenbio develops extracellular vesicle (EV) therapeutics derived from mesenchymal stem cells, using its FT-01 platform to enable scalable, GMP-ready EV manufacturing for regenerative medicine. The company is advancing a licensing-ready production platform and preclinical therapeutic candidate (MEV-N01) targeting rheumatoid arthritis.
- Who are Mesenbio's investors?
- Mesenbio's investors include DSW Ventures.